# name
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

# metadata.dc.contributor.author[].value
The Seom Hereditary Cancer Working Group And Aegh Hereditary Cancer Committee

# metadata.dc.description.abstract[].value
Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype-phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals.

# metadata.dc.relation.ispartof[].value
Clinical and Translational Oncology, 2023, vol. 25, num. 9, p. 2627-2633

# metadata.dc.rights[].value
cc-by (c) Sánchez Heras, Ana Beatriz et al., 2023

# metadata.dc.source[].value
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)